Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model
P. Bessiere, M. Wasniewsk, E. Picard-Meyer, A. Servat, T. Figueroa, C. Foret-Lucas, A. Coggon, S. Lesellier, F. Boue, N. Cebron, B. Gausseres, C. Trumel, G. Foucras, F. J. Salguero, E. Monchatre-Leroy, R. Volmer
This study shows that intranasal type I interferon treatment is effective only when given before clinical signs onset in a SARS-CoV-2 hamster model, not after symptoms appear.
bioRxiv · Feb 9, 2021Microbiology